ArticleWorld journal of surgical oncology2020
DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
Article in World journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- XCR1: A promising prognostic marker that pinpoints targeted and immune-based therapy in hepatocellular carcinoma.Heliyon · 2024Article
- Establishment and verification of a prognostic risk score model based on immune genes for hepatocellular carcinoma in an Asian population.Translational cancer research · 2023Article
- Proteomics of adjacent-to-tumor samples uncovers clinically relevant biological events in hepatocellular carcinoma.National science review · 2023Article
- Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis.Immunology · 2023Article
- Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma.World journal of surgical oncology · 2022Article
- A pyroptosis-related gene signature predicts prognosis and immune microenvironment in hepatocellular carcinoma.World journal of surgical oncology · 2022Article
- Neutrophils as potential therapeutic targets in hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2022Review
- Screening and analysis of RNAs associated with activated memory CD4 and CD8 T cells in liver cancer.World journal of surgical oncology · 2022Article
- Screening of co-pathogenic genes of non-alcoholic fatty liver disease and hepatocellular carcinoma.Frontiers in oncology · 2022Article
- Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.Bioengineered · 2021Article
- Prognostic value of immune-related lncRNA pairs in patients with bladder cancer.World journal of surgical oncology · 2021Article
- Prognostic significance of CD163+ tumor-associated macrophages in colorectal cancer.World journal of surgical oncology · 2021Article
- Identification of ABCC5 Among ATP-Binding Cassette Transporter Family as a New Biomarker for Hepatocellular Carcinoma Based on Bioinformatics Analysis.International journal of general medicine · 2021Article
- CDCA3 Is a Novel Prognostic Biomarker Associated with Immune Infiltration in Hepatocellular Carcinoma.BioMed research international · 2021Article
- Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer.Journal of inflammation research · 2021Article
- Identification of Key Genes in Purine Metabolism as Prognostic Biomarker for Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundDeoxycytidine kinase (DCK), an enzyme in the nucleoside biosynthetic pathway, can affect the development of immune cells. However, the relationships between the expression of DCK, patient prognosis, and tumor-infiltrating immune cells (TIICs) in hepatocellular carcinoma (HCC) are still unclear.
methodsThe expression of DCK in HCC was analyzed through the Oncomine and Tumor Immune Estimation Resource (TIMER) databases. The impact of DCK on clinical prognosis was investigated via the Kaplan-Meier plotter and verified in the Gene Expression Profiling Interactive Analysis (GEPIA) databases. The interrelationships between DCK expression and TIICs in HCC were analyzed by the TIMER database. Additionally, the relationship between DCK expression and immune cell gene markers was calculated through TIMER and GEPIA databases.
resultsCompared with the adjacent normal tissues, high expression of DCK was observed in HCC tissues. Also, the higher expression of DCK was correlated to poorer prognosis in HCC patients, and it was associated with decreased survival in those with early stage and grade. Moreover, DCK expression was positively correlated with TIICs, including CD4
conclusionThese findings suggest that DCK expression is correlated with patient outcomes and tumor infiltration cell levels in HCC patients. Additionally, the increased level of DCK was associated with marker genes of Tregs and exhaustion-related inhibitory receptors, suggesting the potential role of DCK in immunosuppression and immune escape. These findings suggest that DCK can function as a potential novel prognostic biomarker and reflect the immune infiltration status in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.